ENTRY       D11108                      Drug
NAME        Cemiplimab (USAN);
            Cemiplimab (genetical recombination) (JAN);
            Cemiplimab-rwlc;
            Libtayo (TN)
PRODUCT     LIBTAYO (Regeneron Pharmaceuticals)
SEQUENCE    (Heavy chain)
            EVQLLESGGV LVQPGGSLRL SCAASGFTFS NFGMTWVRQA PGKGLEWVSG ISGGGRDTYF
            ADSVKGRFTI SRDNSKNTLY LQMNSLKGED TAVYYCVKWG NIYFDYWGQG TLVTVSSAST
            KGPSVFPLAP CSRSTSESTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
            SLSSVVTVPS SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
            PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV
            SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP SQEEMTKNQV
            SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF
            SCSVMHEALH NHYTQKSLSL SLGK
            (Light chain)
            DIQMTQSPSS LSASVGDSIT ITCRASLSIN TFLNWYQQKP GKAPNLLIYA ASSLHGGVPS
            RFSGSGSGTD FTLTIRTLQP EDFATYYCQQ SSNTPFTFGP GTVVDFRRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H131-L214, H144-H200, H223-H'223, H226-H'226, H258-H318, H364-H422, H'22-H'96, H'131-L'214, H'114-H'200, H'258-H'318, H'364-H'422, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FF06
            Product: D11108<JP/US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  DISEASE   Squamous cell carcinoma [DS:H00040]
            Basal cell carcinoma [DS:H00039]
            Non-small cell lung cance [DS:H00014]
  TYPE      Monoclonal antibody
COMMENT     Treatment of cancer
TARGET      PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  PATHWAY   hsa04514(5133)  Cell adhesion molecules
            hsa04660(5133)  T cell receptor signaling pathway
            hsa05235(5133)  PD-L1 expression and PD-1 checkpoint pathway in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF06 Cemiplimab
                  D11108  Cemiplimab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Cemiplimab
                D11108  Cemiplimab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11108  Cemiplimab (USAN); Cemiplimab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D11108  Cemiplimab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D11108  Cemiplimab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDCD1 (PD1, CD279)
                 D11108  Cemiplimab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11108
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11108
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11108
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11108
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11108
DBLINKS     CAS: 1801342-60-8
            PubChem: 376219032
///
